Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 8551427.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We studied the antibody response to pneumococcal serotypes 3 and 14 after pneumococcal polysaccharide vaccine was administered to 41 children with renal disease. One month after vaccination, 76% and 61% of patients achieved at least a twofold titer rise to serotypes 3 and 14, respectively; this finding was comparable to historic control values. One year after vaccination, the majority of patients retained protective antibody levels. Achieving a titer > or = 1.0 microgram/ml IgG at 1 month was highly predictive of retaining a protective antibody level > or = 0.15 microgram/ml at 1 year.
Medical subject headings
- Antibodies, Bacterial
- Bacterial Vaccines
- Immunoglobulin G
- Kidney Failure, Chronic
- Streptococcus pneumoniae